Remdesivir and tocilizumab: Mix or match

To date, no therapy has demonstrated definite efficacy for patients with COVID‐19. Antiviral, as well as, anti‐inflammatory approaches, as these represented by remdesivir (RDV) and tocilizumab (TCZ) use, have been recently put forward. However, data upon optimal choice of one over the other, or pote...

Full description

Saved in:
Bibliographic Details
Published inJournal of Medical Virology Vol. 93; no. 1; pp. 56 - 58
Main Authors Akinosoglou, Karolina, Velissaris, Dimitris, Ziazias, Dimitris, Davoulos, Christos, Tousis, Alexandros, Tsiotsios, Konstantinos, Kalogeropoulou, Christina, Spyridonidis, Alexandros, Marangos, Markos, Fligkou, Foteini, Gogos, Charalampos
Format Journal Article Web Resource
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.01.2021
Wiley Subscription Services, Inc
John Wiley and Sons Inc
Subjects
Adenosine Monophosphate - analogs & derivatives
Alanine - analogs & derivatives
Antibodies, Monoclonal, Humanized
Antiviral drugs
COVID-19 - drug therapy
Cytokine Release Syndrome
Humans
Immunosuppressive agents
Letter to the Editor
Monoclonal antibodies
Receptors, Interleukin-6
SARS-CoV-2
Virology
Online AccessGet full text

Cover

More Information
Summary:To date, no therapy has demonstrated definite efficacy for patients with COVID‐19. Antiviral, as well as, anti‐inflammatory approaches, as these represented by remdesivir (RDV) and tocilizumab (TCZ) use, have been recently put forward. However, data upon optimal choice of one over the other, or potential need for regimen combination, remains an open question. We hereby report two well‐matched cases of SARS‐CoV‐2 (+) patients, developing respiratory failure, both receiving TCZ following severe inflammatory response, with or without RDV. We argue that, RDV administration is pivotal early in the course of the disease, since TCZ use alone cannot ensure inflammation control.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.26117